JP2021510733A5 - - Google Patents

Info

Publication number
JP2021510733A5
JP2021510733A5 JP2020558865A JP2020558865A JP2021510733A5 JP 2021510733 A5 JP2021510733 A5 JP 2021510733A5 JP 2020558865 A JP2020558865 A JP 2020558865A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2021510733 A5 JP2021510733 A5 JP 2021510733A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
cycloalkyl
cycloalkenyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013375 external-priority patent/WO2019140322A1/en
Publication of JP2021510733A publication Critical patent/JP2021510733A/ja
Publication of JP2021510733A5 publication Critical patent/JP2021510733A5/ja
Priority to JP2024015651A priority Critical patent/JP2024099510A/ja
Pending legal-status Critical Current

Links

JP2020558865A 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ Pending JP2021510733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015651A JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616831P 2018-01-12 2018-01-12
US62/616,831 2018-01-12
PCT/US2019/013375 WO2019140322A1 (en) 2018-01-12 2019-01-11 Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015651A Division JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Publications (2)

Publication Number Publication Date
JP2021510733A JP2021510733A (ja) 2021-04-30
JP2021510733A5 true JP2021510733A5 (https=) 2022-02-08

Family

ID=65516716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558865A Pending JP2021510733A (ja) 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Country Status (7)

Country Link
US (2) US12128018B2 (https=)
EP (1) EP3737362B1 (https=)
JP (2) JP2021510733A (https=)
CN (1) CN112135610A (https=)
CA (1) CA3125731A1 (https=)
ES (1) ES3057234T3 (https=)
WO (1) WO2019140322A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
US20240226039A1 (en) * 2021-05-24 2024-07-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune checkpoint inhibitor and hdac inhibitor combination therapy strategy
WO2023034440A1 (en) 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors
CN113754587B (zh) * 2021-09-22 2023-07-14 沈阳药科大学 一种苯基吡唑类化合物及应用
KR20230084416A (ko) * 2021-12-03 2023-06-13 연세대학교 산학협력단 Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE670584C (de) 1936-07-09 1939-01-20 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von o-Aminophenolen
DE1108213B (de) 1959-02-28 1961-06-08 Frantisek Sorm Dr Ing Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren
SE370866B (https=) 1968-03-21 1974-11-04 Ciba Geigy Ag
JPS4825500B1 (https=) 1970-12-29 1973-07-30
US3850931A (en) 1971-06-25 1974-11-26 American Home Prod 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPS57102887A (en) 1980-12-18 1982-06-26 Otsuka Pharmaceut Co Ltd Preparation of benzo(ij)quinolizine-2-carboxylic acid derivative
US4404356A (en) 1981-09-09 1983-09-13 Ciba-Geigy Corporation Heat-curable epoxide resin compositions
JPS5853916A (ja) 1981-09-09 1983-03-30 チバ−ガイギ−・アクチエンゲゼルシヤフト 熱硬化性エポキシド樹脂組成物
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
DE3511110A1 (de) 1985-03-27 1986-10-02 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
GB8508588D0 (en) 1985-04-02 1985-05-09 Akzo Nv Indene & napthalene derivatives
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
DE3830054A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
JPH03232868A (ja) 1990-02-05 1991-10-16 Nippon Telegr & Teleph Corp <Ntt> 新規光学活性化合物及び液晶組成物
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
JPH06122669A (ja) 1991-12-28 1994-05-06 Ishihara Sangyo Kaisha Ltd ジアミノベンゼン誘導体を含有するホスホリパーゼａ２阻害剤
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
JPH09227495A (ja) 1996-02-16 1997-09-02 Tanabe Seiyaku Co Ltd フェノール誘導体及びその製法
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
FR2805741B1 (fr) 2000-03-06 2003-06-20 Oreal Composition de teinture d'oxydation des fibres keratiniques avec un derive particulier de la paraphenylenediamine et un colorant direct particulier
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
ATE448306T1 (de) 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
JP4183923B2 (ja) 2001-03-29 2008-11-19 富士フイルム株式会社 熱現像感光材料
CA2442557C (en) 2001-04-12 2008-12-23 F. Hoffmann-La Roche Ag Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
WO2005025557A1 (en) 2003-09-16 2005-03-24 Monash University An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005033562A2 (en) * 2003-10-02 2005-04-14 Jesel, Inc. Double roller cam follower
EP1677731A4 (en) 2003-10-09 2009-05-06 Aton Pharma Inc THIOPHENE AND BENZOTHIOPHENE DERIVATIVES OF HYDROXAMIC ACID
US20080070954A1 (en) 2003-10-27 2008-03-20 S*Bio Pte Ltd. Acylurea Connected And Sulfonylurea Connected Hydroxamates
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US20060008517A1 (en) 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
MX2007001550A (es) 2004-08-09 2007-04-10 Astellas Pharma Inc Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac).
CN101039927A (zh) 2004-09-09 2007-09-19 财团法人乙卯研究所 5－羟色胺5－ht3受体激动剂
CA2612420A1 (en) 2005-06-24 2007-01-04 Merck & Co., Inc. Modified malonate derivatives
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
CN101563327A (zh) 2006-12-19 2009-10-21 健泰科生物技术公司 嘧啶类激酶抑制剂
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
WO2008113255A1 (fr) 2007-03-16 2008-09-25 The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CA2690192A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
JP2011500783A (ja) 2007-10-22 2011-01-06 オーキッド リサーチ ラボラトリーズ リミテッド ヒストンデアセチラーゼ阻害剤
CN101918389A (zh) 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2009076234A2 (en) 2007-12-07 2009-06-18 University Of Maryland, Baltimore Synthesis methods of histone deacetylase inhibitors (hdacis)
ES2494366T3 (es) 2008-02-22 2014-09-15 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzodiacepina y composición farmacéutica
US8093000B2 (en) * 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
US20110178138A1 (en) 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
NZ593447A (en) 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
BRPI1007995A2 (pt) 2009-02-23 2019-09-24 Hoffmann La Roche orto-aminoamidas para o tratamento de cãncer.
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP2012529449A (ja) 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
JP2013509441A (ja) 2009-10-30 2013-03-14 マサチューセッツ インスティテュート オブ テクノロジー 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20140107166A1 (en) 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2834548C (en) * 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
CN102775356B (zh) 2011-05-13 2015-07-22 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
WO2013006739A2 (en) 2011-07-05 2013-01-10 Zia Shlaimoun Method and system for video messaging
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
WO2013067391A1 (en) 2011-11-02 2013-05-10 The Broad Institute, Inc. Fluorescent substrates for determining lysine modifying enzyme activity
CA2759407A1 (en) 2011-12-02 2013-06-02 Marrett Alexander GREEN Grey water recycling systems and valves
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
USRE49240E1 (en) 2013-11-05 2022-10-11 The General Hospital Corporation Inhibitors of histone deacetylase
US20160346240A1 (en) 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
CA2941716A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3568127A4 (en) 2017-01-10 2020-11-04 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCESSES USING AN EPIGENETIC INHIBITOR
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2021510733A5 (https=)
JP2022512156A5 (https=)
JP2009532486A5 (https=)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
RU2019115392A (ru) Производные тиенопиррола для применения для нацеливания на белки, композиции с указанными производными, способы и применения
CA2405521A1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
RU2019133646A (ru) Изохинолины в качестве ингибиторов hpk1
JP2006515858A5 (https=)
JP2013544812A5 (https=)
CA2410662A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
RU2000117278A (ru) Производное 2-арил-8-оксодигидропурина, способ для его получения, содержащая его фармацевтическая композиция, и промежуточное соединение
BRPI0310094B1 (pt) composto de bis-(monoetanolamina) de ácido 3&#39;-[(2z)-[1-(3,4-dimetilfenil)-1,5-diidro-3-metil-5-oxo-4h-pirazol-4-ilideno]hidrazino]-2&#39;-hidróxi-[1,1&#39;-bifenil]-3-carboxílico, composição farmacêutica e processos para preparar ditos composto e composição farmacêutica
CA2497868A1 (en) Heterocyclic compounds
CA2409741A1 (en) Tnf-.alpha. production inhibitors
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2024530956A5 (https=)
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
RU2314292C2 (ru) Производные азетидина в качестве антагонистов ccr-3 рецептора
CA2518224A1 (en) Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
RU2004104329A (ru) Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов
RU2019128534A (ru) Химические соединения для лечения туберкулеза
JP2021514399A5 (https=)
CA3127502A1 (en) Formulations comprising heterocyclic protein kinase inhibitors
RU2005136131A (ru) Фармацевтическая композиция, содержащая антагонист р2х7 рецептора и фактор некроза опухоли